Bribery & corruption
ICIJ review finds nearly $1.7 billion in pharma fines failed to deter alleged misconduct
According to an ICIJ investigation, enforcement actions against cancer drug manufacturers across 31 countries over 15 years resulted in nearly $1.7 billion in combined settlements and fines between 2010-2025, yet these penalties represent only one-third of 1% of the firms' revenues.


























































































































































































































:quality(80)/outremer%2F2020%2F11%2F26%2F5fbfa845d47fa_000_hr02x-1530570.jpg)











:quality(80)/outremer%2F2024%2F10%2F01%2F010-gtt19a05-081-66fbce8c0fd75815915529.jpg)











:quality(80)/outremer%2F2025%2F05%2F05%2Fpolice-voit-6818ed5822901148647480.jpg)





































































































































































































